Title of Invention

A GRANULAR PARTICLE

Abstract

"A GRANULAR PARTICLE" The present invention relates to a granular particle comprising: (a) solid solution of an amorphous, pharmaceutically active agent in an amount of about 5% to about 60% by dry weight of the granular particle and a pharmaceutically acceptable hydrophobic vehicle in an amount of about 3% to about 55% by dry weight of the granular particle, wherein said pharmaceutically active agent is normally crystalline and sparingly-water soluble; (b) a stabilizer in an amount of about 1% to about 60% by dry weight of the granular particle comprising a polyethylene glycol, sugars, sorbitol, mannitol, polyvinylpyrrolidone, or one or more cellulose ethers; and (c) a disintegrant comprising croscarmellose sodium, sodium starch glycolate, crospovidone, or a cross-linked polyacrylate.

Full Text

FORM 2 THE PATENTS ACT 1970 [39 OF 1970] & THE PATENTS RULES, 2003 COMPLETE SPECIFICATION [See Section 10; rule 13] "A GRANULAR PARTICLE" R.P. SCHERER TECHNOLOGIES, INC., of 2030 East Flamingo Road, Suite 260, Paradise Valley, Nevada 89119, United States of America, The following specification particularly describes the invention and the manner in which it is to be performed: The present invention relates to a granular particle. This invention relates to methods and formulations for improving the aqueous solu¬bility of crystalline pharmaceutical compounds having low water solubility by converting them to an amorphous state that is stabilized in a granular pharmaceutical formulation. In-particular, it relates to improving the aqueous solubility and bioavailability of azole antifun¬gal medicaments by converting them to the amorphous state, stabilizing this state, and granulating them to form a stabilized granulation thereof. It also relates to pharmaceutical formulations prepared by such methods, to solid dosage forms prepared therefrom, and sta¬bilized aqueous solutions thereof. BACKGROUND OF THE INVENTION Many crystalline, pharmaceutical compounds have very slight solubility in aqueous fluids such as those found in the human body. It is well known that changing a crystalline compound into its amorphous state will substantially increase the aqueous solubility of the compound, thereby increasing its bioavailability. Methods which have been used heretofore to improve aqueous solubility of spar¬ingly soluble active ingredients include inclusion complexation of the active ingredient with amorphous, chemically modified cyclodextrins. Although the active ingredient is not con¬verted from the crystalline state to the amorphous state, the active ingredient/cyclodextrin complex improves solubility of the sparingly soluble ingredients. In some cases it is possible to melt the crystalline active agent, holding it in the molten state for a finite time and then allow it to cool to an amorphous solid. This method is limited to particular active ingredients whichcan produce stable amorphous solids and which are not degraded by the heating step. European patent publication 0852140 Al discloses a method of converting a spar¬ingly soluble medical substance to a more water-soluble amorphous state, in which a mix¬ture of a sparingly water-soluble medical substance, an amorphous state inducing agent and an amorphous state-stabilizing agent, such as hydroxypropyhnethylcellulose, is reported to be heated to a temperature at which the medical substance becomes amorphous. A methylene chloride solution of an antifungal agent which is dissolution-induced dried by any of several methods, e.g., spray dried, initially at a slow rate and then at a higher rate, produces an amorphous powder of the active ingredient. This powder may then be compacted and dry granulated with excipients to be used in tablets or hard gelatin capsules. 5 In another procedure to produce amorphous antifungal agents, the agent and hy- droxypropylmethylcellulose are dissolved in a methylene chloride/alkanol solution. This solution is then sprayed onto spheres such as sugar spheres in a fluidized bed. A seal coat¬ing is then applied to the coated spheres which may then be used to fill hard gelatin cap¬sules. 10 In another procedure to form an amorphous solid dispersion, a sparingly soluble ac- tive agent has been combined with polyvinylpyrrolidone when both components are molten and then allowed to cool. This method reportedly produces a more rapid dissolution of the active agent in water. A further method for stabilizing itraconazole in its amorphous state is through melt- 15 extruding a mixture of itraconazole and a water soluble polymer, as set forth in International Application PCT\EP97\02507. The above methods appear to have varying degrees of success in improving the solubility of a sparingly soluble active agent. However, significant improvement in bio¬availability also requires that the resulting solution of the active ingredient be stable. With-20 out this stabilization, crystallization and precipitation of the dissolved active agent may oc¬cur, thereby reducing the bioavailability of the active agent that has not yet been absorbed into the patient's bloodstream. SUMMARY OF THE INVENTION In accordance with the present invention, improved solubility and bioavailability of 25 a sparingly water-soluble, crystalline pharmaceutically active agent, such as itraconazole, involves melting a normally solid hydrophobic vehicle, such as glyceryl monostearate, dis¬solving therein a sparingly water-soluble, normally crystalline (that is a compound which is, prior to processing hereunder into its amorphous form, crystalline and sparingly water-soluble at ambient temperature pressure) pharmaceutically active agent at a temperature 30 above the normal melting temperature of the vehicle but below the normal melting or deg- radation temperature of active agent, then granulating the molten product with a disintegrant and optional additives. In a first embodiment, a stabilizer is added to the molten solution prior to granulation. In a second embodiment the molten solution is granulated with a mix¬ture of a stabilizer and a disintegrant. In the first embodiment the granulation is preferably 5 conducted in a cooled granulation bed to rapidly cool the stabilized product. In the second embodiment the granulation is conducted at elevated temperature and the resulting granulate is rapidly cooled following a brief granulation period. The resulting granular particles may then be milled to an appropriate particle size, and filled into capsules, or blended with other excipients and processed into solid dosage forms. 10 The resulting product of this invention thus comprises a granular formulation in which the granular particles comprise a solid solution of an amorphous pharmaceutically active agent which is normally crystalline and sparingly water-soluble at ambient tempera¬ture and pressure, dissolved in a molten solution of a pharmaceutically acceptable normally solid hydrophobic vehicle in which the active agent is soluble at elevated temperature; a 15 stabilizing agent to stabilize the active agent in its amorphous state; a disintegrant; and op¬tionally a binder, wherein the dissolved active agent is substantially stabilized in an amor¬phous state as a solid solution in said granular particles. Thus a complete, ready-to-use granular formulation is provided in which the amor¬phous state of the active agent is stabilized for an extended period of time as a solid solution 20 of the amorphous active in the matrix of the hydrophobic vehicle, thereby increasing the solubility and bioavailability of the pharmaceutically active agent when ingested and pass¬ing into aqueous media such as that found in the stomach and providing an extended shelf life for the granulation and products made therefrom. DETAILED DESCRIPTION OF THE INVENTION 25 The novel formulations of this invention that are useful to solubilize sparingly water- soluble normally crystalline pharmaceutically active agents in aqueous media include a normally solid hydrophobic vehicle, one or more stabilizers, binders, and disintegrants. Ba¬sic to the solubilization of a normally crystalline active agent is the necessity of converting it to its amorphous state as a solid solution, and then stabilizing the amorphous state, thus 30 preventing reversion to the crystalline state. The formulations of this invention accomplish this stabilization of the amorphous state of an active agent and maintain it for extended pe¬riods of time, providing an extended shelf life for the active agent during which it has im¬proved solubility and bioavailability. A further, unexpected benefit of these formulations is the stabilization of solutions that are prepared from the granular formulations of the solubi-lized active agent. Such solutions are or may be essentially supersaturated with respect to the intrinsic solubility of the active ingredient, but stabilization in accordance with the pres¬ent invention substantially prevents recrystallization from occurring. The novel granular formulations of this invention thus comprise (a) a solid solution of a pharmaceutically active agent which is sparingly water-soluble its normal crystalline state; (b) a normally solid hydrophobic vehicle for said pharmaceutically active agent such that said vehicle is capable of dissolving said pharmaceutically active agent at a temperature above the melting point of said vehicle but below the normal melting point of said pharma¬ceutically active agent; (c) a stabilizer comprising a member selected from the group con¬sisting of a polyethylene glycol, sugars, sorbitol, mannitol, polyvinylpyrrolidone, and cel¬lulose ethers such as methylcellulose, hydroxypropylmethylcellulose, and hydroxypropyl-cellulose and the like; (d) a disintegrant comprising a member selected from the group con¬sisting of croscarmellose sodium, sodium starch glycolate, crospovidone, and a cross-linked polyacrylate, wherein the normally sparingly water-soluble active agent is dissolved and stabilized in an amorphous state as a solid solution in said vehicle. Depending on the active ingredient and the amounts of the various components, the granulation of this invention may also include a binder, filler or other conventional excipients. More particularly, the granular formulations of this invention are those in which the granular particles comprise (a) a solid solution of the pharmaceutically active agent in a substantially amorphous state in a solid matrix of the vehicle, more specifically, a solid so¬lution of an amorphous, pharmaceutically active agent and the pharmaceutically acceptable hydrophobic vehicle, wherein the pharmaceutically active agent is normally crystalline and sparingly water soluble at ambient pressure and temperature and wherein said pharmaceuti¬cally active agent is dissolved and stabilized in a substantially amorphous state in a molten solution of said vehicle; (b) a stabilizer, and (c) a disintegrant. As used in this application, the phrase 'solid solution' means the active agent has been subjected to a treatment in which the active agent is dissolved in a molten solution of the hydrophobic vehicle and, through additional processing, is solidified. Suitable vehicles for the pharmaceutically active agent are pharmaceutically accept¬able hydrophobic vehicles which are normally solid at ambient temperature, but which melt 5 without degradation at temperatures below the normal melting or degradation temperature of the pharmaceutically active agent. In addition the characteristics of the vehicle must be such that it is capable of dissolving the active agent at a temperature above its own melting point but below the melting point of the active agent. More specifically the vehicles of this invention should have a melting point above about 60°C and should be stable to a tempera- 10 ture up to the temperature at which the active ingredient becomes soluble in the vehicle. Depending on the active ingredient the vehicle should be stable at least to 140°C, and more preferably to a temperature up 250°C or even slightly higher. Further it must not be volatile or evaporate or degrade when heated to such temperatures. The precise choice of vehicle will depend in part on the active agent and in particular on its solubility profile. For solubi- 15 lization of azole fungicides such as itraconazole a preferred vehicle is glyceryl monoste- arate, however various other long chain monoglycerides, diglycerides, and triglycerides, and waxes, including beeswax and microcrystalline wax, and mixtures thereof may also be suit¬able vehicles for the purpose of this invention. The total amount of vehicle that may be used effectively ranges from about 3% to about 55% by dry weight of the granular formula- 20 tion. In a preferred embodiment in which glyceryl monostearate is the vehicle, its concen¬tration should be from about 5% to about 50 % by dry weight of the formulation, more pref¬erably about 5% to about 35%. In addition to acting as a vehicle for dissolution of the active agent, it is probable that the vehicles used in this invention may also serve a second beneficial function in the 25 granular formulation, namely to stabilize or assist in the stabilization of the active ingredient in its amorphous state and thus to prevent it from reverting to its normal crystalline state during and after granulation. Stabilizers conventionally employed to stabilize the active agent in its amorphous state and prevent reversion to its normal crystalline state are also employed in the invention. 30 These materials also serve as pore formers and are necessary in these granular formulations to promote the entrance of water into the body of the granules containing the stabilized amorphous active agent. By providing a path for the water to enter the granules, the disss lution of the amorphous active agent is promoted. Suitable stabilizers include polyethyle glycols, other polyols, sugars, sorbitol, mannitol, polyvinylpyrrolidone, and cellulose eth such as, for example, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcell 5 lose, and mixtures thereof. A preferred stabilizer which also serves as a pore former for granules of the active agent is hydroxypropylmethylcellulose. The stabilizer is suitably pra-sent in the granular formulations of this invention in the range of about 1% to about 60% weight of the dry granulation, preferably about 1% to about 50%. Glycerin may also be employed in the present formulation and when present is be-10 lieved to assist as a pore former and in some instances as an aid to dissolution of the activ ingredient, but is not believed to exhibit any substantial benefit in stabilizing the active agent in its amorphous form. When used it may be suitably employed at about 15% to about 30% by weight of the dry granular particles of this invention. Appropriate disintegrants to be used in these formulations are referred to as super 15 disintegrants. Included in this category are croscarmellose sodium (cross-linked car- boxymethylcellulose), sodium starch glycolate, crospovidone (cross-linked polyvinylpyrron lidone), and cross-linked polyacrylates. A preferred disintegrant is croscarmellose sodiun which may be present in the formulation from about 1% to about 25% by dry weight of th formulation, preferably from about 3% to about 25%. 20 Binders may be selected from microcrystalline cellulose, cellulose floe, starch, sug ars, e.g., lactose or sucrose, calcium phosphate, calcium carbonate, and kaolin. A preferre binder is microcrystalline cellulose, such as Avicel® PH-101. The range in which the bind is present is from about 5% to about 35% by dry weight of the formulation, preferably from about 5% to about 20%. 25 Suitable active agents are those which are normally crystalline at ambient tempera- ture and in that state are no more than sparingly soluble in aqueous media, have a melting point between 50°C and 200°C and possibly as high as about 300°C, may be converted to their amorphous state by heating, and tend to revert to the normal insoluble crystalline stat when cooled and re-solidified. In general the term sparingly soluble as applied to active 30 agents for use in the present invention relates to active agents which in their normal crystal line form have very limited aqueous solubility at ambient temperature, which include sub¬stances whose solubilities range from slightly soluble (=1:100 to 1:1000) to insoluble (more than 1:10,000). By stabilizing these active agents in their amorphous state in a solution of a hydrophobic vehicle either prior to or during granulation, a stabilized granulation is pro-5 vided in which the active agent is stabilized in that amorphous state for extended periods of time, thereby providing desirable shelf life and increasing their solubility and bioavailabil¬ity. Actives having a melting point below about 50°C would not be expected to be stabi¬lized, at least for the period required for a satisfactory shelf life. Further, the active agent must be stable at or above the temperature at which it dissolves in the molten stabilizer. If 10 decomposition occurs, it not only reduces the amount of active present in the formulation, but it also presents the possibility of decomposition products being introduced into the for¬mulation. From a manufacturing perspective, temperatures in excess of about 250°C be¬come increasingly expensive, making other methods of solubilization and stabilization more economical. 15 For example, this method of increasing active agent solubility is applicable to the class of antifungal agents referred to as azoles, including ketoconazole, itraconazole, saper-conazole, fluconazole, miconazole, and the like. All members of this class of active agents have very low solubility in aqueous media and will benefit from the method of conversion to the amorphous state and stabilization of that state that is described herein. More specifi- 20 cally, it has been applied to itraconazole very effectively. The concentration of itraconazole can be varied to provide a particular dosage in a convenient form. Typically this concentra¬tion may range from about 5% to about 60% by weight of the granular formulation. In a preferred formulation this concentration range is about 20% to about 35%. Formulations of this invention containing itraconazole have demonstrated a high rate 25 of dissolution. Within 30 minutes 36-86% of the itraconazole dissolved in simulated gastric juice. By comparison, after 30 minutes under the same conditions, only 1% of crystalline itraconazole had dissolved. After 60 minutes, these values increased to 45-95% for the amorphous, stabilized itraconazole compared with only 2% for the crystalline material. Not only was the solubility of the itraconazole dramatically increased, but also the resulting so-30 lution was stabilized so that itraconazole did not recrystallize and precipitate from the solu¬tion. Mention has been made of the stabilizing effect of the novel formulations described herein on the aqueous solutions produced by dissolution of the formulations. Although it may be possible to identify components of the formulation which have a greater probability of effecting the stabilization of these solutions, it is believed that the entire formulation and 5 the interaction of its components is required for this stabilization to occur to the extent that has been observed. Accordingly, the granular particle of this invention may comprise from 20% to about 35% of pharmaceutically active agent, preferably itraconazole, about 5% to about 35% of the hydrophobic vehicle, preferably glyceryl monostearate, about 3% to about 25% of the disintegrant, preferably croscarmellose, and about 1% to about 50% of the stabi-10 lizer, preferably hydroxypropylmethyl cellulose, all by dry weight of the granular particle. In one particularly preferred embodiment the granular particle described generally above contains from about 15% to about 25% hydroxypropylmethylcellulose, most prefera¬bly about 20%, and about 5% to about 15% of microcrystalline cellulose as a binder, most preferably about 10%, as illustrated in example 5. 15 In another particularly preferred embodiment the granular particle contains from about 30 to 35%) active agent, preferably itraconazole, about 5% to 15% glyceryl monoste¬arate, about 10% to 15% croscarmellose sodium, and 45%) to about 55% hydroxypropyl¬methylcellulose, all by weight of the granular particle, as illustrated in examples 6 and 7. In the first method aspect of this invention, the preparation of the stabilized granular 20 formulations of this invention involves the following steps: (a) heating the hydrophobic vehicle to a temperature at which the vehicle melts and to or slightly above a temperature at which the active agent dissolves in the molten vehicle; (b) dissolving the pharmaceutically active agent in the molten vehicle to form a molten solution of the pharmaceutically active agent in said vehicle; 25 (c) adding a stabilizing amount of the stabilizer to the molten solution; (d) granulating the molten mixture from (c) with a disintegrant and optionally a binder at a temperature below about 30°C, preferably below about 5 °C; thereby forming granular particles comprising a solid solution of the pharmaceutically active agent stabilized in its more soluble amorphous form in the hydrophobic vehicle. In the second method aspect of this invention, the preparation of these formulations is modified to comprise the following steps: (a) heating the hydrophobic vehicle to a temperature at which the vehicle melts and to or slightly above a temperature at which the active agent dissolves in the molten vehicle; 5 (b) dissolving the pharmaceutically active agent in the molten vehicle to form a molten solution of the pharmaceutically active agent in the vehicle; (c) granulating the molten solution with a mixture of the stabilizer, the disintegrant and optionally a binder at or above the temperature at which the active agent dissolves in the stabilizer, to form a granulate; and 10 (d) rapidly cooling the resulting granulation. The temperature at which the active agent dissolves may, in some cases, be lower than the melting temperature of the active agent. It must, however, be high enough to cause the solution to form rapidly and completely. In the first embodiment the stabilizer is added directly to the molten solution of vehicle and active agent and the resulting molten product 15 is then granulated with a cold mixture of a binder and disintegrant and optionally other ex- cipients, under conditions which will cause rapid cooling of the molten material as granula¬tion proceeds, thereby minimizing the amount of active ingredient which can revert to its normal insoluble crystalline state. For example the granulator may suitably be operated at ambient temperature or at any temperature below about 30°C, but is preferably operated at a 20 temperature below about 5°C. In the second mode the stabilizer, rather than being added directly to the molten solution, is instead mixed with the disintegrant and optionally one or more binders or other excipients, and the molten solution is then granulated with that mix¬ture. For this embodiment the granulator is preferably operated at or about the temperature at which the active agent dissolves in the vehicle, thereby stabilizing the active agent in the 25 amorphous state before it has an opportunity to revert to its normal crystalline state, then rapidly cooling the granulate, suitably by discharging the hot granulate through liquid nitro¬gen. It will be appreciated by those skilled in the art that depending on the specific prop¬erties of the active agent and the vehicle, that even under ideal conditions there may be 30 small amounts of active agent which will not dissolve in the vehicle and therefore do not convert to the amorphous state, but such amounts are believed to be insignificant relative to the large proportion of material that goes into the solid solution which forms the basis for this invention. A small portion thereof may revert to the normal water-insoluble crystalline state of the active ingredient, thereby reducing the amount of active available for treatment 5 of disease. While these amounts are difficult to quantify using known analytical techniques, it is believed and it is desirable that at least 85% of the active ingredient, advantageously 90%, or preferably at least 95% to 99% or even 100% of the active ingredient used be pres¬ent in the granules as an amorphous solid in the resulting solid solution. It will also be apparent to those skilled in the art that if the dissolution temperature is 10 too high and/or elevated temperature is maintained for too long a period of time during processing, that the active agent may partially degrade forming degradation products in the granular particles. The selection of which the two modes of operation to choose and/or the precise con¬ditions under which to operate either of them may depend on several factors. Both modes 15 have been shown to be viable and useful options which achieve the foregoing objectives with itraconazole and glyceryl monostearate. In general however, it is preferred to carry out the dissolution step at or about the lowest temperature at which the active agent dissolves in the vehicle, and to avoid heating the vehicle and/or solution of vehicle and active agent to a temperature above that at which the active ingredient begins to undergo significant degra- 20 dation. With itraconazole, dissolution and processing of the stabilized solution is preferably carried out at a temperature below the melting point of itraconazole. Although it may be preferable to use a high shear granulator to produce the final formulation, it is possible that granulators such as extrusion granulators, fluid bed granula- tors, spray congealers, and spray dryers may be used equally well, provided the necessary 25 cooling is available to firmly establish the amorphous character of the active ingredient. If the particles of the final granulation are undesirably large, it is suitable to grind them and screen them to a more acceptable, more uniform size. In this case, the grinding may be done with effective cooling, e.g., that amount of cooling which is necessary to pre¬vent reversion of the active ingredient to the crystalline state and at the same time provide sufficient brittleness for effective grinding. Using liquid nitrogen or some other method of cooling is generally acceptable. Granules that are produced by this invention may be placed directly into hard gelatin capsules to create the final dosage form. A lubricant or a flow aid can be added to these 5 granules to improve flowability into the capsules, if necessary. Additionally, materials granulated by the method of the second aspect of this invention may benefit from the granulate being dry blended with a binder, and, optionally, an additional disintegrant. If, on the other hand, it is desired to compress the granules into tablets using a tableting machine, the addition of a lubricant may be necessary to prevent the processing problems associated 10 with this operation. Both methods of delivery are contemplated as being part of this inven¬tion. The following examples are provided to demonstrate the methods of making and using this invention, but they are only to be construed as being exemplary of the invention, and not as limiting it. Those skilled in the art will understand that obvious variations can be 15 used and are included within this invention. In these examples, unless otherwise specifically stated, all percentages are in weight % of the granular formulation, and all temperatures are in degrees centigrade. Further, the dissolution rate of each formulation was determined using a USP Appa¬ratus 2 (paddle), operated at 100 rpm and containing 900 mL of simulated gastric fluid 20 without pepsin. This fluid was heated to 37°C, and a sample of the granulation containing 100 mg of the active agent was employed. Measurements were taken after 30 minutes and 60 minutes. To determine the total amount of active that was soluble, the stirring was in¬creased to 200 rpm after the 60 minute reading, and the final reading was taken two hours later. This final determination provides a crude measure of the effectiveness of the stabili- 25 zation of the amorphous state by the formulation; 100% dissolution equates to complete conversion to the amorphous state and 100% stabilization of that state. Example 1 A beaker containing 11.88 grams of glycerin was heated to between 90°C and 100°C. To the hot glycerin was added 11.88 grams of glyceryl monostearate (Eastman 30 Chemical Company). This mixture was stirred until the glyceryl monostearate was fully dispersed, and then the temperature was raised to between 130oC and 150oC at which time 12.50 grams of itraconazole was added to the molten mixture. Stirring was continued until the itraconazole was fully dissolved, yielding a clear solution. To this solution was added 1.25 grams of hydroxypropylmethylcellulose E4M (Dow Chemical Company) with contin- 5 ued stirring. Simultaneously, a mixture of 12.50 grams of microcrystalline cellulose (Avicel® PH-101, FMC Corporation) and 12.50 grams of croscarmellose sodium (Ac-Di-Sol®, FMC Corporation) was placed in a granulator bowl cooled in a water bath at 25°C. The molten mixture was then added to the solids in the granulator bowl with mixing until the temperature of the entire mixture reached 25-3 0°C. Dissolution testing showed that 10 43% of the itraconazole dissolved in 30 minutes, and after 60 minutes the dissolved itraco¬nazole increased to 51%. Under the same conditions, the values for the dissolution of crys¬talline itraconazole were determined to be 1% and 2% at 30 and 60 minutes, respectively. Example 2 By the method of Example 1, 7.5 grams of glycerin, 7.5 grams of glyceryl monoste- 15 arate, and 15.5 grams of itraconazole were melted together. The itraconazole went into so- lution at 144°C. To this molten mixture was added 1.5 grams of methylcellulose A15C. The viscosity of the resulting dispersion appeared to be lower than the viscosity of the com¬parable dispersion in Example 1. This dispersion was then granulated with a mixture of 15.5 grams of Avicel® PH-101 and 2.5 grams of croscarmellose sodium. Dissolution test-20 ing determined that 43% of the itraconazole had dissolved in 30 minutes. After 60 minutes this value had increased to 54%. Example 3 By the method of Example 1,11.88 grams of glycerin, 5.94 grams of glyceryl monostearate, and 12.5 grams of itraconazole were melted together. To this molten mixture 25 was added 1.25 grams of hydroxypropylmethylcellulose E4M. The molten phase mixed well and was very fluid. This dispersion was then granulated with a mixture of 7.37 grams of Avicel® PH-101 and 7.37 grams of croscarmellose sodium. This granulation was com¬prised of relatively small granules and appeared to be particularly uniform in appearance. Dissolution testing determined that 51% of the itraconazole had dissolved in 30 minutes. 30 After 60 minutes this value had increased to 61 %. Example 4 By the method of Example 1,11.88 grams of glycerin, 2.97 grams of glyceryl monostearate, and 12.5 grams of itraconazole were melted together. The itraconazole went into solution at 140°C. To this molten mixture was added 1.25 grams of hydroxypropyl-5 methylcellulose E4M which thickened the molten mixture to a greater extent and more rap¬idly than had been observed in Example 3. This dispersion was then granulated with a mixture of 12.5 grams of Avicel® PH-101 and 12.5 grams of croscarmellose sodium. Dis¬solution testing determined that 47% of the itraconazole had dissolved in 30 minutes. After 60 minutes this value had increased to 56%. 10 Example 5 A stainless steel beaker containing 180 grams of glyceryl monostearate (Eastman Chemical Company) was heated to 100°C. When the glyceryl monostearate had melted, the temperature was increased to 145°C, and then 180 grams of crystalline itraconazole was added slowly while maintaining the temperature between 145°C and 155°C. Stirring was 15 continued until the itraconazole was fully dissolved, yielding a clear solution. To this solu¬tion was added 120 grams of hydroxypropylmethylcellulose E5 (Dow Chemical Company) with continued stirring. Simultaneously, a mixture of 60 grams of microcrystalline cellu¬lose (Avicel® PH-101, FMC Corporation) and 60 grams of croscarmellose sodium (Ac-Di-Sol®, FMC Corporation) was placed in a high shear granulator bowl cooled to -4.2°C. The 20 molten mixture was then added to the solids in the granulator bowl at a rate to maintain the temperature of the granulation below 5°C. The blade of the granulator was operated at 312 rpm with the chopper at #1 setting. Upon completion of the addition of the molten mixture, mixing was continued for an additional five minutes until the temperature was below -1°C. The granulation required 95 minutes to complete. This granulation was milled while being 25 cooled with liquid nitrogen through a coarse screen. A second milling operation, also cooled with liquid nitrogen, was accomplished using a Fitz mill, Model M5 fitted with a 60 mesh (250 micron) wire screen. The finished granulation was suitable for use in filling hard gelatin capsules. These granules when tested for dissolution in simulated gastric juice at 37°C were shown to provide solutions containing 86% of the available itraconazole after 30 30 minutes. This, value increased to 95% after 60 minutes. After three hours under the condi¬tions described above, 100% of the itraconazole had dissolved. Example 6 In a stirred kettle heated to 150-165°C was placed on 0.25 Kg of glyceryl monoste¬arate. When the glyceryl monostearate was completely molten, the slow addition of 1.5 Kg of itraconazole was begun. Upon completion of addition, the mixture was heated and stirred 5 until all of the itraconazole was completely, dissolved. Simultaneously, a dry blend of 2.25 Kg of hydroxypropylmethylcellulose E5 (Dow Chemical Company) and 0.60 Kg of cro-scarmellose sodium (Ac-Di-Sol®, FMC Corporation) was placed in a high shear granulator heated to 150°C. After the dry mixture had attained a temperature of 150°C and, with the main blade of the granulator operating at 300 rpm and the cross screw operated at full speed, 10 the molten mixture of glyceryl monostearate and itraconazole was pumped from the kettle into the granulator during a period of one minute. After 1.5 minutes of granulation, the granulated mixture was discharged into a stream of liquid nitrogen, rapidly cooling and so¬lidifying the granulate. The granulate was milled using a Fitz mill, Model M5, fitted with a 1512-0027 perforated screen, and cooled with liquid nitrogen. The milled granulate was 15 then placed in a twin shell blender, and 0.4 Kg of Avicel Ph-200 was added and blended to prepare the final formulation to be used to fill hard gelatin capsules. Using the test condi¬tions described in Example 5, the powdered granulate provided dissolution of 87% after 30 minutes and 94% after one hour. For comparison, the capsules provided 84% dissolution after 30 minutes and 98% after one hour, indicating that there was no significant difference 20 between the two dissolution tests. Example 7 In a separate run, the granular particles of this example were prepared, milled and blended as provided in example 6, except that the granular particle was blended with 0.25Kg of microcrystalline cellulose and 0.15Kg talc to facilitate blending and handling of 25 the finished formulation. The finished blend of granular particles and additives thus con¬tains 30% itraconazole, 5% glyceryl monostearate, 12% croscarmellose sodium, 45% HPMC, 5% microcrystalline cellulose and 3% talc, by weight of the resulting blend. The dissolution results were consistent with those obtained for example six. WE CLAIM: 1. A granular particle comprising: (a) solid solution of an amorphous, pharmaceutically active agent in an amount of about 5% to about 60% by dry weight of the granular particle and a pharmaceutically acceptable hydrophobic vehicle in an amount of about 3% to about 55% by dry weight of the granular particle, wherein said pharmaceutically active agent is normally crystalline and sparingly-water soluble; (b) a stabilizer in an amount of about 1% to about 60% by dry weight of the granular particle comprising a polyethylene glycol, sugars, sorbitol, mannitol, polyvinylpyrrolidone, or one or more cellulose ethers; and (c) a disintegrant comprising croscarmellose sodium, sodium starch glycolate, crospovidone, or a cross-linked polyacrylate. 2. The granular particle as claimed in claim 1, wherein the pharmaceutically active agent is an azole fungicide. 3. The granular particle as claimed in claim 2, wherein the azole fungicide is itraconazole. 4. The granular particle as claimed in claim 3, wherein itraconazole is present at about 20% to about 35% by dry weight of the granular particle. 5. The granular particle as claimed in claim 1, wherein the hydrophobic vehicle comprises glyceryl monostearate, a monoglyceride, a diglyceride, a triglyceride, or a wax. 6. The granular particle as claimed in claim 5, wherein the hydrophobic vehicle comprises glyceryl monostearate. 7. The granular particle as claimed in claim 6, wherein the glyceryl monostearate is present at about 5% to about 35% by dry weight of the granular particle. 8. The granular particle as claimed in claim 1, wherein the stabilizer is hydroxypropylmethylcellulose. 9. The granular particle as claimed in claim 1, wherein the disintegrant is croscarmellose and is present at about 1% to about 25% by dry weight of the granular particle. 10. The granular particle as claimed in claim 1, further comprising a binder comprising microcrystalline cellulose, flocculated cellulose, starch, a sugar, calcium phosphate, calcium carbonate or kaolin. 11. The granular particle as claimed in claim 10, wherein the binder is microcrystalline cellulose and is present at about 5% to about 35% by dry weight of the granular particle. 12. A granular particle as claimed in claim 1 comprising: (a) a solid solution of amorphous itraconazole and glycerol monostearate, wherein said itraconazole is normally crystalline, sparingly water-soluble, and present in an amount of about 20% to about 35% by dry weight of said granular particle, and said glycerol monosearate is present in an amount of about 5% to about 35% by dry weight of said granular particle; (b) a stabilizer comprisng a hydroxypropylmethylcellulose in an amount of about 1% to about 50% by dry weight of said granular particle; and (c) a disintegrant comprising croscarmellose sodium in an amount of about 3% to about 25% by dry weight of said granular particle. 13. The granular particle as claimed in claim 12, comprising about 15% to about 25% hydroxypropylmethylcellulose by dry weight of said granular particle and further comprising about 5% to about 15% microcrystalline cellulose by dry weight of said granular particle. 14. The granular particle as claimed in claim 12, wherein said itraconazole is present in an amount of about 30% to about 35% by dry weight of said granular particle, said glycerol monostearate is present in an amount of 5% to 15% by dry weight of said granular particle, said croscarmellose sodium is present in an amount of about 10% to 15% by dry weight of said granular particle and said hydroxypropylmethylcellulose is present in an amount of 45% to about 55% by dry weight of said granular particle. Dated this 4th day of July, 2005. [SHUKADVEKHURAIJAM] OF REMFRY & SAGAR FOR THE APPLICANTS

Documents:

708-mumnp-2005-abstract(granted)-(6-6-2008).doc

708-mumnp-2005-abstract-(6-6-2008).pdf

708-mumnp-2005-cancelled pages-(6-6-2008).pdf

708-mumnp-2005-claims(granted)-(6-6-2008).doc

708-mumnp-2005-claims(granted)-(6-6-2008).pdf

708-MUMNP-2005-CORRESPONDENCE 20-6-2008.pdf

708-mumnp-2005-correspondence(6-6-2008).pdf

708-mumnp-2005-correspondence(ipo)-(4-11-2008).pdf

708-mumnp-2005-form 1(6-6-2008).pdf

708-mumnp-2005-form 13(9-6-2008).pdf

708-mumnp-2005-form 18(3-1-2006).pdf

708-mumnp-2005-form 2(granted)-(6-6-2008).doc

708-mumnp-2005-form 2(granted)-(6-6-2008).pdf

708-mumnp-2005-form 3(3-6-2005).pdf

708-mumnp-2005-form 3(6-6-2008).pdf

708-mumnp-2005-form 5(30-6-2005).pdf

708-mumnp-2005-other documents(6-6-2008).pdf

708-mumnp-2005-petition under rule 137(9-6-2008).pdf

708-mumnp-2005-petition under rule 138(9-6-2008).pdf

708-MUMNP-2005-POWER OF ATTORNEY 20-6-2008.pdf